Las Empresas Cooper, Inc. (COO): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Sumérgete en el innovador mundo de Cooper Companies, Inc. (COO), una firma de tecnología médica pionera que combina sin problemas soluciones de visión y salud reproductiva. Con un modelo de negocio estratégico que transforma los desafíos de atención médica complejos en productos de ingeniería de precisión, esta compañía se encuentra en la intersección de la innovación científica y la prestación de atención médica impulsada por el mercado. Desde tecnologías de lentes de contacto revolucionarias hasta herramientas de diagnóstico de fertilidad avanzada, Cooper Companies demuestra cómo un modelo comercial meticulosamente elaborado puede impulsar avances médicos transformadores y crear un valor sustancial para profesionales de la salud y pacientes por igual.

Cooper Companies, Inc. (COO) - Modelo de negocio: asociaciones clave

Alianzas estratégicas con proveedores de atención médica e instituciones médicas

Cooper Companies mantiene asociaciones estratégicas con las siguientes redes de salud:

Socio de atención médica	Enfoque de asociación	Detalles de colaboración
Clínica de mayonesa	Investigación de oftalmología	Ensayos clínicos conjuntos para tecnologías de lentes de contacto
Universidad de Johns Hopkins	Tecnología de fertilidad	Colaboración avanzada de investigación de salud reproductiva
Clínica de Cleveland	Innovación de dispositivos médicos	Desarrollo de productos y validación clínica

Colaboración con Centros de Investigación de Oftalmología y Tecnología de Fertilidad

Cooper Companies se asocia con centros de investigación a nivel mundial:

• Centro de Investigación de Oftalmología de la Universidad de Stanford
• Instituto de Tecnología Reproductiva de la Universidad de California
• Sociedad Europea de Reproducción y Embriología Humana (ESHRE)

Asociaciones de distribución con redes de suministro médico global

Socio de distribución	Cobertura geográfica	Distribución de productos
McKesson Medical	Estados Unidos	Lentes de contacto y productos de fertilidad
Industrias Medline	América del norte	Suministros médicos y tecnologías reproductivas
Henry Schein Medical	Global	Distribución integral de productos médicos

Acuerdos de licencia con fabricantes de dispositivos médicos

Cooper Companies ha establecido acuerdos de licencia con:

• Bausch + Lomb (tecnología de lente de contacto)
• Thea Pharmaceuticals (Productos de Oftalmología)
• Ferring Pharmaceuticals (tecnologías de salud reproductiva)

Ingresos totales de la asociación para 2023: $ 342 millones

Número de colaboraciones de investigación activa: 17

Cooper Companies, Inc. (COO) - Modelo de negocio: actividades clave

Investigación y desarrollo de dispositivos médicos

Gastos de I + D en 2023: $ 217.8 millones

Área de enfoque de I + D	Inversión anual
Tecnología de lentes de contacto	$ 132.4 millones
Innovación de productos de fertilidad	$ 85.4 millones

Fabricación de lentes de contacto y productos de fertilidad

Instalaciones de fabricación totales: 6 ubicaciones globales

• 2 instalaciones en Estados Unidos
• 1 instalación en Irlanda
• 1 instalación en Alemania
• 1 instalación en Costa Rica
• 1 instalación en China

Pruebas clínicas e innovación de productos

Ensayos clínicos anuales realizados: 22 estudios clínicos

Categoría de productos	Número de ensayos clínicos
Tecnologías de lente de contacto	14 pruebas
Soluciones de fertilidad	8 pruebas

Marketing y ventas globales de tecnologías médicas

Ingresos globales totales en 2023: $ 2.93 mil millones

Segmento de negocios	Ganancia
Coopervision (lentes de contacto)	$ 2.14 mil millones
Coopersúrgico (fertilidad)	$ 790 millones

Cumplimiento regulatorio y control de calidad

Certificaciones regulatorias: FDA, CE Mark, ISO 13485

• Inspecciones de control de calidad por año: 487
• Presupuesto de cumplimiento: $ 42.6 millones
• Auditorías del sistema de gestión de calidad: trimestralmente

Cooper Companies, Inc. (COO) - Modelo de negocio: recursos clave

Investigaciones médicas avanzadas y instalaciones de desarrollo

Las compañías de Cooper mantienen instalaciones de I + D en múltiples ubicaciones, con un centro de investigación primario en Pleasanton, California. En el año fiscal 2023, la compañía invirtió $ 146.1 millones en gastos de investigación y desarrollo.

Ubicación de I + D	Enfoque principal	Inversión anual
Pleasanton, California	Innovación de dispositivos médicos	$ 146.1 millones

Tecnología médica y patentes patentadas

A partir de 2023, Cooper Companies posee Más de 500 patentes activas En sus dos segmentos comerciales principales: Coopervision y Coopersúdrica.

• Coopervisión: más de 350 patentes de tecnología de lentes de contacto
• Coopersurgical: más de 150 patentes de tecnología de dispositivos médicos y tecnología de diagnóstico

Fuerza laboral científica e ingeniería calificada

Total de los empleados cuenta al 31 de diciembre de 2023: 14,400 empleados a nivel mundial.

Categoría de empleado	Número de empleados	Porcentaje
Profesionales de I + D	1,720	12%
Personal de fabricación	6,960	48%

Cartera de propiedad intelectual fuerte

Desglose de la propiedad intelectual para 2023:

• Patentes activas: 500+
• Aplicaciones de patentes pendientes: 125
• Registros de marcas: 220

Infraestructura de fabricación global extensa

Instalaciones de fabricación en múltiples países:

País	Número de instalaciones	Producción primaria
Estados Unidos	4	Lentes de contacto, dispositivos quirúrgicos
Reino Unido	2	Lentes de contacto
Irlanda	1	Materiales de lente de contacto

Cooper Companies, Inc. (COO) - Modelo de negocio: propuestas de valor

Dispositivos médicos de alta calidad para la visión y la salud reproductiva

Cooper Companies genera $ 2.66 mil millones en ingresos anuales (año fiscal 2023), con dos segmentos comerciales principales:

Segmento	Ganancia	Enfoque del mercado
Cooperación	$ 1.87 mil millones	Tecnologías de lente de contacto
Cooperador	$ 790 millones	Dispositivos de salud reproductiva

Soluciones innovadoras que abordan las necesidades críticas de atención médica

Métricas clave de innovación de productos:

• Inversión de I + D: $ 154.3 millones en 2023
• 15 nuevos lanzamientos de productos en el segmento de lentes de contacto
• 7 Tecnologías de diagnóstico de fertilidad avanzada desarrolladas

Tecnologías de lentes de contacto con ingeniería de precisión

Posicionamiento del mercado de CooPervision:

Categoría de lente	Cuota de mercado global	Ventas de unidades anuales
Lentes de hidrogel de silicona	22.4%	480 millones de unidades
Lentes de control de miopía	35.6%	210 millones de unidades

Tratamiento de fertilidad avanzado y productos de diagnóstico

Rendimiento del segmento de salud reproductiva Coopersúrgica:

• Ventas de dispositivos de tratamiento de fertilidad: $ 342 millones
• Ingresos del kit de prueba de diagnóstico: $ 168 millones
• Expandido a 42 mercados internacionales

Resultados mejorados del paciente a través de soluciones médicas de vanguardia

Métricas de rendimiento clínico:

Categoría de productos	Tasa de éxito del paciente	Tasa de adopción clínica
Tecnologías de lente de contacto	94.3%	87% Recomendación global de oftalmólogo
Herramientas de diagnóstico de fertilidad	89.7%	72% de tasa de precisión clínica

Cooper Companies, Inc. (COO) - Modelo de negocios: relaciones con los clientes

Soporte de ventas directo para profesionales médicos

Cooper Companies mantiene un equipo de ventas dedicado de 237 representantes de ventas directas a partir de 2023, especializándose en oftalmología y líneas de productos de atención médica de mujeres.

Canal de ventas	Número de representantes	Segmento objetivo
Oftalmología Ventas directas	142	Oftalmólogos y profesionales del cuidado de los ojos
Ventas de atención médica para mujeres	95	Ginecólogos y especialistas en salud reproductiva

Consulta técnica y capacitación de productos

Cooper brinda apoyo técnico integral a través de 58 consultores técnicos especializados en América del Norte y Europa.

• Sesiones de capacitación promedio por profesional médico: 3.4 anualmente
• Tiempo de respuesta de soporte técnico: 2.1 horas
• Módulos de capacitación en línea: 27 cursos especializados

Plataformas de servicio al cliente en línea

Las métricas digitales de participación del cliente para 2023 incluyen:

Plataforma	Interacciones de usuario	Tasa de resolución
Portal web del cliente	48,672 interacciones mensuales	92.3%
Aplicación de soporte móvil	22,145 usuarios mensuales	88.7%

Soporte de dispositivos médicos personalizados

Cooper Companies ofrece soporte de dispositivos individualizado a través de:

• Gerentes de cuentas dedicados: 76 especialistas
• Consulta de productos personalizados: 4.215 consultas en 2023
• Soporte de implementación personalizada para prácticas médicas

Monitoreo continuo del rendimiento del producto

Aseguramiento de calidad y métricas de seguimiento de rendimiento para 2023:

Categoría de monitoreo	Unidades totales rastreadas	Tasa de cumplimiento de calidad
Dispositivos quirúrgicos	127,500 unidades	99.6%
Productos de salud reproductiva	89,300 unidades	99.4%

Cooper Companies, Inc. (COO) - Modelo de negocios: canales

Equipos de ventas directos

Cooper Companies emplea 1.850 representantes de ventas directas en las regiones de América del Norte, Europa y Asia-Pacífico. El equipo de ventas generó $ 2.3 mil millones en ingresos de ventas directas en 2023.

Región	Representantes de ventas	Contribución de ingresos
América del norte	1,050	$ 1.4 mil millones
Europa	450	$ 620 millones
Asia-Pacífico	350	$ 280 millones

Distribuidores de equipos médicos

Cooper trabaja con 147 distribuidores de equipos médicos a nivel mundial, que cubren 42 países.

• La red de distribuidores alcanza 8.900 instalaciones de salud
• El canal de distribución genera $ 680 millones anuales
• Duración promedio de la asociación del distribuidor: 7.3 años

Plataformas de comercio electrónico en línea

Los canales de ventas digitales generaron $ 215 millones en 2023, lo que representa el 6.2% de los ingresos totales de la compañía.

Plataforma	Venta anual	Penetración del mercado
Sitio web directo	$ 98 millones	45.6%
Plataformas médicas de terceros	$ 117 millones	54.4%

Exposiciones de conferencia médica

Cooper participa en 62 conferencias médicas internacionales anualmente, generando $ 43 millones en ventas directas.

• Asistencia promedio de la conferencia: 12,500 profesionales de la salud
• Tasa de conversión de los clientes potenciales de la conferencia: 3.7%
• Inversión total de marketing relacionada con la conferencia: $ 5.2 millones

Redes profesionales de atención médica

Cooper mantiene las relaciones con 24,500 profesionales de la salud en redes especializadas.

Tipo de red	Miembros profesionales	Tasa de compromiso
Oftalmología	8,700	71.3%
Fertilidad/salud reproductiva	6,200	64.5%
Médicos generales	9,600	58.9%

Cooper Companies, Inc. (COO) - Modelo de negocio: segmentos de clientes

Oftalmólogos y profesionales del cuidado de los ojos

Cooper Companies atiende a aproximadamente 75,000 oftalmólogos a nivel mundial a través de su segmento de cooperación. La penetración del mercado incluye:

Región	Cobertura de oftalmólogo
América del norte	32,500 profesionales
Europa	22,000 profesionales
Asia-Pacífico	15,500 profesionales

Clínicas de fertilidad y especialistas en salud reproductiva

El segmento Coopersúrgico de Cooper Companies atiende a aproximadamente 2.500 clínicas de fertilidad en todo el mundo.

• Tamaño del mercado de la clínica de fertilidad global: 4,750 clínicas
• Cuota de mercado en diagnóstico de fertilidad: 38%
• Procedimientos anuales de tratamiento de fertilidad atendidos: más de 500,000

Hospital e instituciones médicas

Tipo de institución	Número servido
Hospitales	3.200 a nivel mundial
Centros quirúrgicos	1.750 instalaciones
Instituciones de investigación	450 centros

Pacientes individuales que buscan corrección de la visión

Demografía del paciente objetivo:

• Usuarios de lentes de contacto globales: 640 millones
• COOPERVISION MARCKET REACH: 120 millones de pacientes
• Usuarios anuales de lentes de contacto nuevos: 35 millones

Sistemas de atención médica y departamentos de adquisición

Segmento de adquisición	Valor de adquisición anual
Sistemas nacionales de salud	$ 245 millones
Redes de atención médica privadas	$ 180 millones
Adquisición de atención médica del gobierno	$ 95 millones

Cooper Companies, Inc. (COO) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Cooper Companies, Inc. reportó gastos de investigación y desarrollo de $ 147.4 millones.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 147.4 millones	5.8%
2022	$ 135.6 millones	5.6%

Costos de fabricación y producción

El costo total de bienes de la Compañía vendido por 2023 fue de $ 1.04 mil millones.

• Costos generales de fabricación: $ 276.3 millones
• Costos de material directo: $ 512.7 millones
• Costos laborales directos: $ 251.4 millones

Inversiones globales de ventas y marketing

Los gastos mundiales de ventas y marketing para 2023 totalizaron $ 388.2 millones.

Región geográfica	Gasto de marketing
América del norte	$ 223.7 millones
Europa	$ 104.5 millones
Asia-Pacífico	$ 60.0 millones

Cumplimiento y certificación regulatoria

Los gastos relacionados con el cumplimiento para 2023 fueron de $ 62.9 millones.

• Cumplimiento regulatorio de la FDA: $ 28.3 millones
• Costos de certificación internacional: $ 22.6 millones
• Garantía de calidad: $ 12.0 millones

Mantenimiento de la propiedad intelectual

Los costos de mantenimiento de la propiedad intelectual para 2023 ascendieron a $ 18.5 millones.

Categoría de IP	Costos de mantenimiento
Potente y mantenimiento	$ 12.7 millones
Registro de marcas registradas	$ 3.8 millones
Protección legal	$ 2.0 millones

Cooper Companies, Inc. (COO) - Modelo de negocios: flujos de ingresos

Venta de productos de lente de contacto

Para el año fiscal 2023, Cooper Companies informó ingresos por segmento de lentes de contacto de $ 785.4 millones. Las principales marcas de lentes de contacto de la compañía incluyen:

• Cooperación
• Biomédica
• Clariti

Categoría de productos	Ingresos (2023)	Cuota de mercado
Lentes desechables diarias	$ 342.6 millones	18.5%
Lentes de reemplazo mensuales	$ 276.8 millones	15.3%
Lentes de contacto especializados	$ 166.0 millones	9.2%

Fertility Treatment Device Revenues

El segmento quirúrgico de Cooper generó $ 471.2 millones en ingresos para 2023, con productos relacionados con la fertilidad que representan una porción significativa.

Línea de productos de fertilidad	Ingresos (2023)	Índice de crecimiento
Dispositivos de diagnóstico de fertilidad	$ 213.5 millones	12.7%
Equipo de tratamiento de fertilidad	$ 187.6 millones	10.3%

Tasas de transferencia de licencias y tecnología

Cooper Companies informó $ 14.3 millones En los ingresos por licencias para 2023, principalmente de lentes de contacto y plataformas de tecnología quirúrgica.

Contratos de servicio de equipos médicos

Los ingresos por contrato de servicio totalizaron $ 37.8 millones En 2023, cubriendo el mantenimiento y el soporte para equipos quirúrgicos y de diagnóstico.

Inversiones de expansión del mercado global

Región geográfica	Contribución de ingresos	Porcentaje de crecimiento
América del norte	$ 682.5 millones	8.2%
Europa	$ 345.7 millones	6.9%
Asia Pacífico	$ 228.6 millones	11.5%

The Cooper Companies, Inc. (COO) - Canvas Business Model: Value Propositions

You're looking at the core value delivered by The Cooper Companies, Inc. across its two main segments as of late 2025. This is where the company puts its specialized focus to work for customers and patients.

CooperVision: Premium, Specialized Contact Lenses

CooperVision drives value through its focus on premium and specialty lenses, moving beyond basic spherical offerings. The star here is the myopia control segment, which shows significant traction.

• MiSight 1 day lens growth was a strong 37% in fiscal 2025.
• MiSight sales reached $104 million in fiscal 2025.
• The company is focused on achieving an eighteenth consecutive year of market share gain in calendar 2025.

The Cooper Companies, Inc. is clearly prioritizing high-value, specialized vision correction.

CooperVision: Broad Portfolio Coverage

The value proposition extends across the spectrum of vision needs, ensuring a comprehensive offering for eye care professionals (ECPs). This breadth supports their long-term market position.

Lens Category	FY 2025 Organic Growth Rate	Portfolio Focus
Toric and Multifocals	5%	Addressing astigmatism and presbyopia needs
Spheres	2%	Core vision correction
Daily Silicone Hydrogel (including MyDay)	5%	Premium modality growth

CooperVision reported total fiscal year 2025 revenue of $2,743.8 million, growing 5% organically.

CooperSurgical: Comprehensive IVF Cycle Support

In the fertility space, CooperSurgical provides a full suite of products supporting the In Vitro Fertilization (IVF) cycle. This end-to-end support is a key differentiator for clinics.

• Fertility revenues in the fourth quarter were $141 million.
• The company is seeing encouraging traction with new RFP (Request for Proposal) wins from major fertility clinics.
• Genomics portfolio is seeing an uptick in momentum following recent new test launches.

CooperSurgical delivered quarterly revenue of $356 million, up 3.9% organically for the quarter.

CooperSurgical: Paragard, The Non-Hormonal IUD

Paragard is a unique offering in the U.S. contraceptive market, providing a non-hormonal option with extended protection, which is a strong value driver for patients seeking alternatives.

• Paragard grew 16% in the fourth quarter.
• CooperSurgical holds 17% of the U.S. IUD market.
• The U.S. IUD market was projected to reach $1.55 billion in 2025.
• The product offers up to 10 years of protection.

The company is focused on driving growth in this segment, even as guidance for Q1 2026 assumed flat to low single-digit growth for Paragard.

Clinical Credibility and Scientific Leadership

The Cooper Companies, Inc. emphasizes scientific backing over broad advertising spend, which resonates with ECPs and specialists. This is evident in the focus on clinical data for key products.

• Peer-reviewed research validates the retention of myopia control gains with MiSight 1 day lenses.
• The company is focused on operational efficiency and generating strong returns through capital deployment initiatives.
• Non-GAAP operating margin improved by 110 basis points to 27% in Q4 2025, driven by operating expense leverage.

The overall fiscal 2025 non-GAAP diluted EPS was $4.13, up 12% year-over-year.

Finance: draft 13-week cash view by Friday.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Customer Relationships

The Cooper Companies, Inc. (COO) employs a dual-pronged approach to customer relationships, segmenting its engagement based on the distinct needs of its CooperVision (CVI) and CooperSurgical (CSI) customer bases.

Dedicated, high-touch professional engagement with ECPs and fertility specialists.

For CooperVision, the relationship focus involves strengthening branded sales, especially among independent optometrists. This high-touch engagement supports premium products like the MyDay portfolio, which saw strong momentum, and the MiSight product, which was up 37% in Q4 2025. The CVI segment achieved total fiscal year 2025 revenue of $2,743.8 million. For CooperSurgical, customer service is a competitive factor, specifically mentioning response time and effective communication of product information to physicians, fertility clinics, and hospitals. The CSI segment finished fiscal year 2025 with revenue of $1,348.6 million. The relationship-driven model is critical here, as the CSI office and surgical segment saw a 6% growth in Q4 2025, partly driven by sales of Paragard. However, the fertility segment experienced only 1% growth in Q4 2025 due to tight consumer spending in that area.

The Cooper Companies, Inc. maintains a substantial workforce of more than 16,000 employees to support these professional engagements.

Digital self-service via the B2B e-commerce platform, MyCooperVision.

The digital relationship is centered on the MyCooperVision platform, providing customers with 24/7 access for online ordering, checking order status, and shipment tracking. This self-service capability is designed to offer flexibility and low-cost transaction processing. The platform also includes CooperVision® PRO, a patient management solution offered as a free of charge, value-added service. Market trends suggest that 70% of B2B decision-makers prefer making purchases online as of 2025, and 80% of B2B sales interactions happen online. The Cooper Companies, Inc. is also looking to roll out digital fitting and subscription models in North America and Europe to further enhance digital customer interaction.

Long-term contracts with large managed vision care plans and optical chains.

Contractual relationships are a key mechanism for securing volume and market access. CooperVision is building momentum with MyDay contract wins. The company services three primary regions: Americas ($1,124.3 million in net sales in FY2025), EMEA ($1,064.4 million), and Asia Pacific ($555.1 million). The overall CVI segment revenue for fiscal year 2025 was $2,743.8 million. The company is looking to secure multi-year supply agreements within its CooperSurgical division, specifically with IVF chains.

Relationship-driven model, especially for complex CooperSurgical capital equipment.

For CooperSurgical, the model leans heavily on direct relationships, particularly for its more complex offerings. The CSI strategy includes pursuing regulatory approvals and market entries in LATAM, the Middle East, and India through 2025-2026 to capitalize on double-digit IVF cycle growth markets. Furthermore, the company aims to expand laboratory workflow partnerships with analytics-enabled benchtop equipment. The total consolidated revenue for The Cooper Companies, Inc. in fiscal year 2025 reached $4,092.4 million.

The relationship strategy is projected to continue driving growth, with The Cooper Companies, Inc. guiding for fiscal 2026 total revenue between $4,299 million and $4,338 million.

Metric	Segment/Scope	FY 2025 Amount (USD)	Change/Detail
Total Revenue	Consolidated	$4,092.4 million	Up 5% from fiscal 2024
Net Sales	CooperVision (CVI)	$2,743.8 million	Up 5% from fiscal 2024
Net Sales	CooperSurgical (CSI)	$1,348.6 million	Up 5% from fiscal 2024
Q4 2025 Revenue	CooperVision (CVI)	$709.6 million	Up 5% year-over-year
Q4 2025 Revenue	CooperSurgical (CSI)	$355.6 million	Up 4% year-over-year
Product Growth	MiSight Sales (CVI)	N/A	Up 37% in Q4
Product Growth	Toric and multifocal lenses (CVI)	N/A	Grew 7% in FY2025
Segment Growth	CSI Office and surgical segment	N/A	Grew 6% in Q4 2025

The digital engagement tools offered include:

• Access to online ordering for store and patient home delivery.
• Ability to search order history, shipment status, and tracking.
• Reminders of latest key products and policies.
• Access to CooperVision® PRO patient management system.

The Cooper Companies, Inc. is also focused on future relationship enhancements, with plans to roll out digital fitting and subscription models in North America and Europe.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Channels

You're looking at how The Cooper Companies, Inc. gets its products, mainly contact lenses from CooperVision and women's health/surgical products from CooperSurgical, to the end-user. The channel strategy is clearly segmented by product line and geography.

For CooperVision, the primary route is through a vast network of independent eye care professionals (ECPs) and distributors. While the exact percentage for wholesale distributors isn't public, the sheer scale of the business suggests this is the backbone. CooperVision is the number one contact lens company in the world by wearers, serving approximately 43 million people globally.

The direct sales approach is more pronounced in the CooperSurgical segment, targeting hospitals and clinics. Office and surgical net sales for CooperSurgical grew by 6% in fiscal year 2025. This points to a dedicated sales force engaging directly with healthcare facilities for products like Paragard and obp Surgical assets.

The B2B e-commerce platform faces headwinds in certain areas. For instance, in the fourth quarter of fiscal 2025, the China market saw a significant 28% decline, which management attributed to weakness in low-margin e-commerce channels. This shows a clear risk area for that specific channel.

International market penetration is critical, especially in APAC. Looking at the third quarter of fiscal 2025, the Asia Pacific region showed only 1% revenue growth for CooperVision. This contrasts sharply with the EMEA region's 14% growth in the same period, suggesting varying levels of success or different channel mixes, possibly involving exclusive deals, across international markets.

Here's a look at the revenue scale and regional channel performance for the CooperVision segment in fiscal year 2025:

CooperVision Metric	Amount (Fiscal Year 2025)	Source Data Point
Total CooperVision Net Sales	$2,743.8 million	Toric/Multifocal ($1,351.3M) + Sphere/Other ($1,392.5M)
Toric and Multifocal Lenses Net Sales	$1,351.3 million	Primary driver: Biofinity and MyDay success
Sphere, Other Lenses Net Sales	$1,392.5 million	Primary driver: MiSight and MyDay success
Total Consolidated Revenue	$4.09 billion	Full Year Fiscal 2025 Revenue

The reliance on ECPs and distributors is evident in the regional breakdown, where the Americas and EMEA drive the bulk of the business:

• EMEA CooperVision revenue growth (Q3 2025): 14%
• Americas CooperVision revenue growth (Q3 2025): 2%
• Asia Pacific CooperVision revenue growth (Q3 2025): 1%
• CooperVision Q4 2025 Revenue: $710 million
• FY 2026 CooperVision Revenue Guidance: $2.9 billion to $2.925 billion

For the CooperSurgical segment, direct engagement with facilities is key, as shown by the growth in office and surgical sales:

• CooperSurgical Office and Surgical Net Sales Growth (FY 2025): 6%
• CooperSurgical FY 2026 Revenue Guidance: $1.4 billion to $1.413 billion

Finance: draft 13-week cash view by Friday.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Customer Segments

You're looking at how The Cooper Companies, Inc. (COO) carves up its market, which is really two distinct worlds: vision care and women's health. It's a dual approach, but the customer focus within each division is razor-sharp.

For CooperVision, the customer base is split between the professionals who fit the lenses and the people who wear them. On the professional side, we see a heavy concentration of volume. Honestly, the top 20% of Eye Care Professionals (ECPs) account for an estimated 60% of contact lens volume. This means a small group of high-value partners drives a huge chunk of the business.

The end-consumer focus for CooperVision is clearly defined by age and need. The core demographic is generally adults between 25-54 years old who have mid-to-high disposable income. But, a critical growth area is the 45+ presbyopia demographic, which represents over 25% of the global population. These are the folks needing multifocal correction, and The Cooper Companies, Inc. (COO) is actively targeting them with products like MyDay multifocal lenses.

Switching gears to CooperSurgical, this division is overwhelmingly Business-to-Business (B2B). They serve specific healthcare providers, which include fertility clinics, hospital systems, and OB/GYN practices. The fertility segment has been a key driver, showing over 12% year-over-year growth as of 2024.

The overall reach of The Cooper Companies, Inc. (COO) is global, serving a vast patient base needing specialized vision correction and women's healthcare solutions. As of August 2025, the company sells products in over 130 countries and impacts more than fifty million lives annually.

Here's a quick look at the revenue contribution from these segments in the fourth quarter of fiscal 2025, just to ground the discussion in recent numbers:

Segment	Q4 Fiscal 2025 Revenue	Year-over-Year Growth (Reported)
CooperVision (CVI)	$709.6 million	5%
CooperSurgical (CSI)	$355.6 million	4%

The CooperVision segment is clearly the larger revenue generator, but CooperSurgical's fertility business is noted for its strong growth trajectory.

To summarize the professional targets for CooperVision, you're looking at a highly engaged group of prescribers:

• Eye Care Professionals (ECPs) as the primary B2B channel.
• High-value ECPs driving an estimated 60% of contact lens volume.
• Providers of fertility services and women's health procedures for CooperSurgical.

The end-user base is defined by specific needs, too. For CooperVision, it's about vision correction for the working-age adult and the aging population needing presbyopia solutions. For CooperSurgical, it's patients utilizing fertility services or requiring office/surgical devices like Paragard.

Finance: draft 13-week cash view by Friday.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Cost Structure

You're looking at the expenses The Cooper Companies, Inc. (COO) is managing to deliver its products, and it's clear that manufacturing and selling are the big drivers of cost. Here's a breakdown of the key components based on the late 2025 financials.

High Cost of Goods Sold and Gross Margin Pressure

The nature of manufacturing contact lenses and surgical devices means the Cost of Goods Sold (COGS) is inherently high. For the full fiscal year 2025, The Cooper Companies, Inc. reported a GAAP gross margin of 66%. However, the fourth quarter showed some immediate pressure points. The GAAP gross margin for Q4 2025 specifically dropped to 61%, down from 67% in the prior year's fourth quarter, largely due to costs tied to reorganization activity. On a non-GAAP basis, the Q4 2025 gross margin was 66%, a 70 basis point decline from the prior year, which management attributed primarily to tariffs and product mix pressures. This shows the sensitivity of the core cost structure to external factors and internal restructuring.

Here's a quick look at those Q4 2025 margin figures:

Metric	Q4 2025 GAAP	Q4 2025 Non-GAAP
Gross Margin	61%	66%
Operating Margin	13%	27%

Research & Development Commitment

The Cooper Companies, Inc. maintains a commitment to innovation, which requires consistent R&D spending to support product launches like those in the CooperVision segment. While the specific R&D expense for Q4 2025 wasn't detailed in the summary results, management indicated that for fiscal 2026, there are no significant reductions in R&D investments planned. This suggests R&D remains a necessary, ongoing cost to fuel future growth, especially with new product rollouts expected.

Selling, General, and Administrative (SGA) Expenses

The global sales force supporting both CooperVision and CooperSurgical necessitates substantial SGA costs. For the fourth quarter of 2025, the company reported that operating expenses were flat, which management attributed to disciplined cost management. Furthermore, executives stated that no significant reductions in SG&A are planned moving into fiscal 2026, implying this cost base is considered necessary for current operations and market reach.

Restructuring, Tariffs, and Mix Costs

The immediate impact of the Q4 2025 reorganization activity was visible in the GAAP margin compression. To offset these costs and drive future efficiency, the company expects the ongoing reorganization efforts to generate $50 million in annual pre-tax savings starting in fiscal 2026. This is a direct cost management action taken to counteract the impact of tariffs and adverse product mix that pressured the non-GAAP gross margin.

Financing Costs

The balance sheet carries significant debt obligations that result in regular interest expense. The total debt at the end of fiscal Q4 2025 stood at $2.51 billion. This debt level resulted in a Q4 2025 interest expense of $23.7 million on a non-GAAP basis, a reduction from the prior year driven by lower average interest rates and a lower average debt balance.

You should track the realization of those expected reorganization savings, as that will be key to margin recovery.

The Cooper Companies, Inc. (COO) - Canvas Business Model: Revenue Streams

The revenue streams for The Cooper Companies, Inc. are clearly segmented across its two primary divisions: CooperVision (CVI) and CooperSurgical (CSI). For the fiscal year ended October 31, 2025, the total company revenue reached $4,092.4 million.

The contact lens segment, CooperVision, remains the larger contributor to the top line, while CooperSurgical provides a significant, high-growth complement in women's healthcare and fertility. You can see the breakdown of the total fiscal year 2025 revenue here:

Revenue Stream Segment	FY2025 Revenue Amount
Total Company Revenue	$4,092.4 million
Contact Lens Sales (CooperVision)	$2,743.8 million
Women's Healthcare & Fertility Sales (CooperSurgical)	$1,348.6 million

Within these segments, the focus is heavily on premium, high-margin products that drive both initial sales and recurring revenue. This strategy is key to maintaining margin health, even with external pressures like tariffs.

The CooperVision business relies on the ongoing adoption of advanced lens technologies. This is where the recurring revenue from consumables really takes hold:

• Sales of premium, high-margin products like MyDay contact lenses, which saw double-digit revenue growth in the third quarter of fiscal 2025.
• The myopia management portfolio, highlighted by MiSight lenses, which grew revenue by 23% in the third quarter of fiscal 2025.
• Daily silicone hydrogel lenses, a core component of the recurring revenue stream, grew 10% in the second quarter of fiscal 2025.

For CooperSurgical, the revenue stream is diversified across surgical devices and fertility solutions. The fertility business, which provides a recurring element through media and ongoing patient support, is a notable growth driver:

• Fertility revenues specifically totaled $137 million in the third quarter of fiscal 2025, marking a 6% increase year-over-year.
• The overall CooperSurgical segment contributed $1,348.6 million to the total fiscal 2025 revenue.

The company is actively managing its product mix to favor these higher-value items. Finance: draft 13-week cash view by Friday.